# Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)

> **NCT01346865** · PHASE4 · TERMINATED · sponsor: **Seung-Jung Park** · enrollment: 402 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Cilostazol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01346865
- **Lead sponsor:** Seung-Jung Park
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 402 (ACTUAL)
- **Why stopped:** Low Recruitment
- **Last updated:** 2015-11-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01346865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01346865, "Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01346865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*